Free Newsletter
Teva downplays Copaxone copying as sales rise
Free newsletter via e-mail
Tools
As Teva Pharmaceutical Industries (NASDAQ: TEVA) Q2 results got a big boost from growing Copaxone sales, executives are saying they're confident that generic knock-offs of the multiple sclerosis drug won't be forthcoming anytime soon. Report | Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: